Cargando…

An immune relevant signature for predicting prognoses and immunotherapeutic responses in patients with muscle‐invasive bladder cancer (MIBC)

Immune checkpoint inhibitors (ICIs) are novel treatments that significantly improve the survival time of MIBC patients, but immunotherapeutic responses are different among MIBC patients. Therefore, it is urgent to find predictive biomarkers that can accurately identify MIBC patients who are sensitiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Wen, Zhu, Dandan, Wang, Chenghe, Zhu, Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7163112/ https://www.ncbi.nlm.nih.gov/pubmed/32096345 http://dx.doi.org/10.1002/cam4.2942

Ejemplares similares

Exploration of Prognostic Biomarkers of Muscle-Invasive Bladder Cancer (MIBC) by Bioinformatics
por: Xu, Xianglai, et al.
Publicado: (2021)

Bladder preservation in non-metastatic muscle-invasive bladder cancer (MIBC): a single-institution experience
por: Gerardi, Marianna A., et al.
Publicado: (2016)

Tumor suppressing effects of tristetraprolin and its small double‐stranded RNAs in bladder cancer
por: Jiang, Wen, et al.
Publicado: (2020)

Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database
por: Del Bene, Gabriella, et al.
Publicado: (2018)

Immunotherapeutic Significance of a Prognostic Alternative Splicing Signature in Bladder Cancer
por: Chen, Jiang, et al.
Publicado: (2022)

A systematic review and meta-analysis of radical cystectomy in the treatment of muscular invasive bladder cancer (MIBC)
por: Zhao, Juan, et al.
Publicado: (2021)

The bladder microbiome of NMIBC and MIBC patients revealed by 2bRAD-M
por: Sun, Jian-Xuan, et al.
Publicado: (2023)

Single dose Tadalafil 5 mg in Muscle Invasive Bladder Cancer (MIBC) patient induce priapism: A case report and literature review
por: Prabharani, Diaswara, et al.
Publicado: (2022)

Intratumoral TIGIT(+) CD8(+) T-cell infiltration determines poor prognosis and immune evasion in patients with muscle-invasive bladder cancer
por: Liu, Zhaopei, et al.
Publicado: (2020)

Prognostic significance of bladder neck involvement in non‐muscle‐invasive bladder cancer: A SEER database analysis with 19,919 patients
por: Zhan, Xiangpeng, et al.
Publicado: (2021)

Estimating the optimal perioperative chemotherapy utilization rate for muscle‐invasive bladder cancer
por: Karim, Safiya, et al.
Publicado: (2019)

Outcomes by time to definitive chemoradiation treatment for patients with muscle-invasive bladder cancer
por: Kotha, Nikhil V., et al.
Publicado: (2022)

Identification of Immune-Related lncRNA Signature to Predict Prognosis and Immunotherapeutic Efficiency in Bladder Cancer
por: Zhang, Lianghao, et al.
Publicado: (2021)

Immune Landscape of Invasive Ductal Carcinoma Tumor Microenvironment Identifies a Prognostic and Immunotherapeutically Relevant Gene Signature
por: Bao, Xuanwen, et al.
Publicado: (2019)

Impact of treatment time‐related factors on prognoses and radiation proctitis after definitive chemoradiotherapy for cervical cancer
por: Huang, Eng‐Yen, et al.
Publicado: (2016)

Identification of an IRGP Signature to Predict Prognosis and Immunotherapeutic Efficiency in Bladder Cancer
por: Zhang, Liang-Hao, et al.
Publicado: (2021)

Intravesical BCG in patients with non-muscle invasive bladder cancer induces trained immunity and decreases respiratory infections
por: van Puffelen, Jelmer H, et al.
Publicado: (2023)

Immune Gene Signatures and Immunotypes in Immune Microenvironment Are Associated With Glioma Prognose
por: Wang, Xiang-Xu, et al.
Publicado: (2022)

Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies
por: Pombo Antunes, Ana Rita, et al.
Publicado: (2020)

Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial
por: Verghote, Flor, et al.
Publicado: (2021)

Metabolomics analysis reveals distinct profiles of nonmuscle‐invasive and muscle‐invasive bladder cancer
por: Sahu, Divya, et al.
Publicado: (2017)

Immune‐related signature predicts the prognosis and immunotherapy benefit in bladder cancer
por: Wang, Yejinpeng, et al.
Publicado: (2020)

Impact of COVID-19 on Management of MIBC: a Quantitative and Temporal Analysis
por: Kombathula, S.H., et al.
Publicado: (2023)

Race modifies survival benefit of guideline‐based treatment: Implications for reducing disparities in muscle invasive bladder cancer
por: Washington, Samuel L., et al.
Publicado: (2020)

Dysbiosis signatures of the microbial profile in tissue from bladder cancer
por: Liu, Fei, et al.
Publicado: (2019)

SPTAN1, APC, and FGFR3 Mutation Status and APOBEC Mutation Signatures are Predictive of Mitomycin C Response in Non-muscle-invasive Bladder Cancer
por: Lindgren, Maria Skydt, et al.
Publicado: (2021)

Immune landscape of advanced gastric cancer tumor microenvironment identifies immunotherapeutic relevant gene signature
por: Zhang, Simeng, et al.
Publicado: (2021)

Comparison of prognoses according to non‐positive and positive spectrin αII expression detected immunohistochemically in epithelial ovarian carcinoma: a retrospective study.
por: Maeda, Osamu, et al.
Publicado: (2016)

Beneficial Use of MIBC in Metakaolin-Based Geopolymers to Improve Flowability and Compressive Strength
por: Lee, Sujeong, et al.
Publicado: (2020)

Study on the Strengthening Mechanism of a MIBC–PEG Mixed Surfactant on Foam Stability
por: Xu, Mengdi, et al.
Publicado: (2023)

Identification of an Autophagy-Related Pair Signature for Predicting Prognoses and Immune Activity in Pancreatic Adenocarcinoma
por: Zhang, Qian, et al.
Publicado: (2021)

Immunogenomic Landscape in Breast Cancer Reveals Immunotherapeutically Relevant Gene Signatures
por: Wang, Tao, et al.
Publicado: (2022)

Clinical characteristics and prognoses of patients treated surgically for metastatic lung tumors
por: Zhao, Xiaoliang, et al.
Publicado: (2017)

Efficacy of intravesical therapies on the prevention of recurrence and progression of non‐muscle‐invasive bladder cancer: A systematic review and network meta‐analysis
por: Lu, Jun‐Lin, et al.
Publicado: (2020)

NXPH4 Used as a New Prognostic and Immunotherapeutic Marker for Muscle-Invasive Bladder Cancer
por: Gui, Zhiming, et al.
Publicado: (2022)

Outcomes for Muscle-invasive Bladder Cancer with Radical Cystectomy or Trimodal Therapy in US Veterans
por: Kumar, Abhishek, et al.
Publicado: (2021)

Role of cytokines in combinatorial immunotherapeutics of non‐small cell lung cancer through systems perspective
por: Misra, Pragya, et al.
Publicado: (2019)

Outcome of patients with nonmetastatic muscle‐invasive bladder cancer not undergoing cystectomy after treatment with noncisplatin‐based chemotherapy and/or radiotherapy: a retrospective analysis
por: Bamias, Aristotle, et al.
Publicado: (2016)

National Cancer Database Comparison of Radical Cystectomy vs Chemoradiotherapy for Muscle‐Invasive Bladder Cancer: Implications of Using Clinical vs Pathologic Staging
por: Lin, Hong‐Yiou, et al.
Publicado: (2018)

Survival after radiotherapy versus radical cystectomy for primary muscle‐invasive bladder cancer: A Swedish nationwide population‐based cohort study
por: Häggström, Christel, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ooltu050ibbjl962brhdvv6i78